CClinicalTrials.gg
CompletedNCT01102205Updated Jun 13, 2013

Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease

An observational study in Hashimoto Disease, sponsored by Vakif Gureba Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-13.

Sponsored by Vakif Gureba Training and Research Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Years to 95 Years
Sex
All
01

Study summary

Oxidative stress leads to or accompanies with numerous disease. Oxidative balance in subclinical hypothyroid or euthyroid state in Hashimoto disease are not known. Effect of levothyroxine therapy on oxidative balance are also not known in hashimoto disease.

Read the detailed description

oxidative stress markers will be measured initially(TAS,TOS,OSI,PARAOXONASE,ARYLESTERASA,PON1 PHENOTYPİNG,LİPİDPEROXİD).After 3 months therapy with levothyroxine measurements will be repeated except PON1 phenotyping.

02

Conditions studied

  • Hashimoto Disease

Browse trials for

03

In context

Hashimoto Disease

88 studies on the registry are indexed under Hashimoto Disease; 25 are open to participants now.

This study's enrollment of 130 is above the median of 110 across 46 observational studies indexed under Hashimoto Disease.

Browse Hashimoto Disease studies →

Lead sponsor

Vakif Gureba Training and Research Hospital is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

adult with Hashimoto disease in euthyroid or subclinical hypothyroid state and healthy control.

Inclusion criteria

  • age more than 18 years

Exclusion criteria

Exclusion Criteria:

  • inability to give a written consent
  • other conditions and drug usage affect oxidative stress
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (actual)
Biospecimen retention
Samples without dna

Groups and cohorts

  • healthy
  • euthyroid hashimoto
  • hypothyroid hashimoto
06

What researchers measure

Primary outcomes

  1. Poxidative stress markers

    Time frame: After levotren therapy

07

Study locations

1 site
  • Vakif Gureba Training and Research Hospital
    Istanbul, 34100, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01102205
Lead sponsor
Vakif Gureba Training and Research Hospital
Responsible party
Mehmet Ali Cikrikcioglu (Vakif Gureba TRH, Vakif Gureba Training and Research Hospital) — Principal investigator
First posted
Apr 13, 2010
Start date
Apr 2010
Primary completion
Apr 2010
Completion
Oct 2010
Last update
Jun 13, 2013

Study contacts

Mehmet ali Cikrikcioglu, MD
study chair · vakif gureba TRH,fatih,istanbul,turkey.specialist in internal medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion